Overcoming resistance to BRAF inhibitors

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Activating mutations in serine/threonine (S/T) kinase BRAF are critical in melanoma initiation and progression.
• The MAPK-pathway is central to BRAF-mutant melanoma, with BRAF and MEK inhibitors yielding high initial response rates.

Purpose of the Study:

• To review the development, application, and clinical effects of BRAF and MEK inhibitors in melanoma targeted therapy.
• To describe resistance mechanisms in patients progressing on these therapies.
• To discuss strategies for optimizing MAPK inhibitor use and alternative combination therapies.

Main Methods:

• Review of scientific literature on BRAF and MEK inhibitors in melanoma.
• Analysis of clinical data regarding response rates and resistance mechanisms.
• Discussion of emerging therapeutic strategies and combination therapies.

Main Results:

• BRAF and MEK inhibitors demonstrate significant initial efficacy but often result in transient responses.
• Disease progression is frequently associated with the emergence of drug-resistance mechanisms that restore MAPK-pathway activity.
• Various resistance mechanisms have been identified in patients treated with targeted therapies.

Conclusions:

• Optimizing MAPK inhibitor therapy and exploring novel combination strategies are essential to overcome resistance.
• Targeting specific resistance mechanisms holds promise for improving durable responses in melanoma patients.
• Further research into combination therapies can delay resistance and enhance treatment efficacy.